

1 **Identification of Adipophilin as a Potential Plasma Biomarker**
2 **for Colorectal Cancer using Label-free Quantitative Mass**
3 **Spectrometry and Protein Microarray**

4
5 Junichi Matsubara,^{1,2} Kazufumi Honda,¹ Masaya Ono,¹ Shigeki Sekine,³
6 Yoshinori Tanaka,⁴ Michimoto Kobayashi,⁴ Gimán Jung,⁴ Tomohiro Sakuma,⁵
7 Shoji Nakamori,⁶ Naohiro Sata,⁷ Hideo Nagai,⁷ Tatsuya Ioka,⁸ Takuji Okusaka,⁹
8 Tomoo Kosuge,⁹ Akihiko Tsuchida,¹⁰ Masashi Shimahara,¹¹ Yohichi Yasunami,¹²
9 Tsutomu Chiba,² and Tesshi Yamada¹

10
11 **Authors' Affiliations:** ¹Division of Chemotherapy and Clinical Research, National
12 Cancer Center Research Institute, Tokyo; ²Department of Gastroenterology and
13 Hepatology, Kyoto University Graduate School of Medicine, Kyoto; ³Division of
14 Molecular Pathology, National Cancer Center Research Institute, Tokyo; ⁴New Frontiers
15 Research Laboratories, Toray Industries, Kamakura; ⁵BioBusiness Group, Mitsui
16 Knowledge Industry, Tokyo; ⁶Department of Surgery, Osaka National Hospital, National
17 Hospital Organization, Osaka; ⁷Department of Surgery, Jichi Medical University,
18 Shimotsuke; ⁸Department of Hepatobiliary and Pancreatic Oncology, Osaka Medical
19 Center for Cancer and Cardiovascular Diseases, Osaka; ⁹Hepatobiliary and Pancreatic
20 Oncology and Hepatobiliary and Pancreatic Surgery Divisions, National Cancer Center
21 Hospital, Tokyo; ¹⁰Third Department of Surgery, Tokyo Medical University, Tokyo;
22 ¹¹Department of Oral Surgery, Osaka Medical College, Osaka; ¹²Department of
23 Regenerative Medicine and Transplantation, Fukuoka University Faculty of Medicine,
24 Fukuoka, Japan

25

1 **Corresponding author:** Junichi Matsubara, MD., PhD., Department of
2 Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine.
3 54 Shogoinkawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan. Phone: 81-75-751-4302;
4 Fax: 81-75-751-4303; E-mail: jmatsuba@kuhp.kyoto-u.ac.jp.

5

6 **Running title:** Adipophilin is a Biomarker for Colorectal Cancer

7

8 **Keywords:** Colorectal cancer, Adipophilin, Proteomics, Mass spectrometry, Protein
9 microarray.

10

11 **Number of figures:** 5 (Figure 1-4 and Supplementary Figure S1)

12 **Number of tables:** 3 (Tables 1-2 and Supplementary Table S1)

13

14 **Abbreviations used in this paper:** **2DICAL**, 2-dimensional image converted analysis
15 of liquid chromatography and mass spectrometry; **AUC**, area under the curve; **CC**,
16 correlation coefficient; **CEA**, carcinoembryonic antigen; **CI**, confidence interval; **CV**,
17 coefficient of variance; **ESI**, electrospray ionization; **FOB**, fecal occult blood; **HFM**,
18 hollow-fiber membrane; **HFMT**, hollow-fiber membrane-based technique; **(HP)LC**,
19 (high-performance) liquid chromatography; **JMS**, Jichi Medical School Hospital; **LMW**,
20 low-molecular weight; **MS**, mass spectrometry; **MS/MS**, tandem mass spectrometry;
21 **m/z**, mass to charge ratio; **NCCH**, National Cancer Center Hospital; **OMC**, Osaka
22 Medical College Hospital; **ONH**, Osaka National Hospital; **Q-TOF**, quadrupole
23 time-of-flight; **ROC**, receiver operating characteristics; **RT**, retention time, **SD**,
24 standard deviation; **TMUH**, Tokyo Medical University Hospital; **UICC**, international
25 union against cancer.

26

1 **ABSTRACT**

2 **Background:** The aim of this study was to identify a new plasma biomarker for use in
3 early detection of colorectal cancer.

4 **Methods:** Using the combination of hollow-fiber-membrane (HFM)-based
5 low-molecular weight protein enrichment and 2-Dimensional Image Converted Analysis
6 of Liquid chromatography and mass spectrometry (2DICAL), we compared the plasma
7 proteome of 22 colorectal cancer patients to those of 21 healthy controls. An identified
8 biomarker candidate was then validated in two larger cohorts [Validation-1 (n = 210)
9 and Validation-2 (n = 113)] using a high-density reverse-phase protein microarray.

10 **Results:** From a total of 53,009 mass peaks, we identified 103 with an area-under-curve
11 (AUC) value of 0.80 or higher that could distinguish cancer patients from healthy
12 controls. A peak that increased in colorectal cancer patients, with an AUC of 0.81 and
13 *P*-value of 0.0004 (Mann-Whitney *U*-test), was identified as a product of the *PLIN2*
14 gene [also known as perilipin-2, adipose differentiation-related protein (ADRP), or
15 adipophilin]. An increase in plasma adipophilin was consistently observed in colorectal
16 cancer patients, including those with stage I or stage II disease (*P* < 0.0001, Welch's
17 *t*-test). Immunohistochemical analysis revealed that adipophilin is expressed primarily
18 in the basal sides of colorectal cancer cells forming polarized tubular structures, and that
19 it is absent from adjacent normal intestinal mucosae.

20 **Conclusions:** Adipophilin is a plasma biomarker potentially useful for the detection of
21 early-stage colorectal cancer.

22 **Impact:** The combination of HFM and 2DICAL enables the comprehensive analysis of
23 plasma proteins and is ideal for use in all biomarker discovery studies.

24

1 **Introduction**

2 Colorectal cancer is the second leading cause of cancer deaths in Western countries (1),
3 and is the third leading cause of cancer deaths in Japan, where there were more than
4 43,000 estimated colorectal cancer deaths in 2008 (2). Treatment of colorectal cancer
5 without metastasis is relatively uncomplicated, and a favorable prognosis can be
6 expected for these patients (3, 4). However, the 5-year survival rate of patients with
7 metastatic colorectal cancer is estimated to be less than 5% (5), underscoring the
8 importance of early detection. The modality used most commonly for colorectal cancer
9 mass screening is fecal occult blood (FOB) test. Three large randomized trials
10 demonstrated that inclusion of FOB in colorectal cancer screening significantly reduces
11 the rates of colorectal cancer mortality (6-8). However, FOB has a relatively high
12 false-positive rate (9, 10), and as a result, a large number of healthy individuals receive
13 radiological or endoscopic re-examination after the FOB test, placing excessive physical
14 and physiological burdens on examiners and examinees, as well as imposing an undue
15 financial burden upon society. The only approved screening alternative to FOB for the
16 diagnosis of colorectal cancer is testing for the tumor marker carcinoembryonic antigen
17 (CEA). Unfortunately, CEA is not useful as a marker for the early detection of
18 colorectal cancer (11). Therefore, it is necessary to identify a new biomarker to
19 supplement these current diagnostic modalities.

20 Alterations in the protein content of clinical samples reflect the dynamic
21 biological changes of patients more directly than changes in mRNA levels (12).
22 Plasma/serum proteins are thus valuable resources for the discovery of biomarkers with
23 direct clinical application. We previously developed a quantitative proteomics platform,
24 called 2DICAL (13). This technology is especially advantageous in clinical studies in
25 which a large number of patient samples must be compared. We were able to identify a

1 number of plasma/serum biomarkers with high potential for clinical application using
2 2DICAL (14-18). However, the direct analysis of plasma/serum proteins using 2DICAL
3 remains technically challenging. Proteins secreted by cancer cells are considerably
4 diluted in the blood circulation and present only in a low concentration (19, 20). The
5 concentration of serum/plasma proteins ranges over more than 10 orders of magnitude,
6 and thus the efficient removal of abundant plasma/serum proteins is essential for the
7 detection of low-abundance cancer-related biomarker proteins (21).

8 In this study we applied a high-performance hollow-fiber membrane (HFM)
9 technology to the enrichment of low-molecular weight (LMW) proteins (17, 22) and
10 searched for new plasma biomarkers that might be applicable to the early diagnosis of
11 colorectal cancer. The LMW plasma protein fraction is made up of various functional
12 proteins, such as cytokines, chemokines, and peptides, and is considered to be a rich
13 unexplored archive of biologic information (20). The HFM-based technique (HFMT)
14 utilizes a fully automated system that can separate and concentrate low-abundance
15 plasma proteins from relatively high-molecular weight abundant proteins such as
16 albumin, immunoglobulin, transferrin, and apolipoproteins with high efficiency and
17 reproducibility (22). Here, we report the identification of adipophilin, an
18 adipose-differentiation-related protein, as a novel tumor marker for colorectal cancer
19 through a comprehensive analysis of the LWM plasma proteome of colorectal cancer
20 patients using HFM and 2DICAL technologies.

21

22

23 **Patients and Methods**

24 **Plasma samples**

25 Plasma samples were collected prospectively from 366 individuals and then split

1 randomly into three cohorts (Training, Validation-1 [V1], and Validation-2 [V2]) (Table
2 1). The cohorts were essentially hospital-based, and consisted of healthy volunteers and
3 newcomers (primarily to gastrointestinal services) between August 2006 and October
4 2008 at the following seven hospitals in Japan: National Cancer Center Hospital
5 (NCCH; Tokyo), Osaka National Hospital (ONH; Osaka), Jichi Medical School
6 Hospital (JMS; Shimotsuke), Osaka Medical Center for Cancer and Cardiovascular
7 Diseases (Osaka), Tokyo Medical University Hospital (TMUH; Tokyo), Osaka Medical
8 College Hospital (OMC; Osaka), and Fukuoka University Hospital (Fukuoka). This
9 multi-institutional collaborative study group was organized by the “Third-Term
10 Comprehensive Control Research for Cancer” conducted by the Ministry of Health,
11 Labour and Welfare of Japan and joined the International Cancer Biomarker Consortium
12 (23). Written informed consent was obtained from every subject.

13 All patients diagnosed as having cancer had histological or cytological proof of
14 colorectal adenocarcinoma. Demographic and laboratory data for the cases are
15 summarized in Table 1. The staging of cancer was defined according to TNM
16 classification by the International Union against Cancer (UICC). The Training cohort
17 comprised 43 cases, including untreated colorectal cancer patients from TMUH ($n = 8$),
18 JMS ($n = 9$), and ONH ($n = 5$), and healthy controls from NCCH ($n = 2$), TMUH ($n = 9$),
19 OMC ($n = 6$), and ONH ($n = 4$). The V1 and V2 cohorts comprised 210 and 113 cases,
20 respectively, from the seven hospitals as described above. The V1 cohort included 101
21 patients with colorectal cancer and 109 healthy controls. The V2 cohort comprised 26
22 patients with colorectal cancer and 87 healthy controls.

23 For all the samples used in this study, the same protocol was used for blood
24 collection, storage, and freeze/thawing to ensure absence of any pre-analytical bias
25 caused by differences in sample handling. Blood was collected in a tube with

1 ethylenediaminetetraacetic acid (EDTA) at the time of diagnosis. Plasma was separated
2 by centrifugation and frozen at -80°C until analysis. Macroscopically hemolyzed
3 samples were excluded from the present analysis. The protocol of this study was
4 reviewed and approved by the institutional ethics committee board of each participating
5 institute.

6

7 **Depletion of high-molecular weight plasma proteins**

8 The plasma samples of the Training cohort were filtered through a 0.22- μ m-pore-size
9 filter. Five hundred microliter of the sample was diluted by adding 3.5 mL 25mM
10 ammonium bicarbonate buffer (pH 8.0). The total of 4 mL of the plasma dilution was
11 injected into a HFMT machine (22). After one hour of fully automated operation, the
12 solution containing LMW proteins was recovered and lyophilized.

13

14 **LC-MS**

15 The HFMT-treated samples were digested with sequencing-grade modified trypsin
16 (Promega, Madison, WI) and analyzed in duplicate using a nano-flow high-performance
17 liquid chromatography (HPLC) (NanoFrontier nLC, Hitachi High-technologies, Tokyo,
18 Japan) connected to an electrospray ionization quadrupole time-of-flight (ESI-Q-TOF)
19 mass spectrometer (Q-Tof Ultima, Waters, Milford, MC).

20 MS peaks were detected, normalized, and quantified using the in-house
21 2DICAL software package, as described previously (13). A serial identification (ID)
22 number was applied to each of the MS peaks detected (1 to 53009). The stability of
23 LC-MS was monitored by calculating the correlation coefficient (CC) and coefficient of
24 variance (CV) of every measurement. For all 53,009 peaks observed in the 43 duplicate
25 runs, the mean CC (\pm SD) was as high as 0.951 (\pm 0.039) and the mean CV was as low

1 as 0.054 (\pm 0.011).

2

3 **Protein identification by tandem mass spectrometry (MS/MS)**

4 Peak lists were generated using the Mass Navigator software package (version 1.2)
5 (Mitsui Knowledge Industry, Tokyo, Japan) and the peak lists were searched against the
6 SwissProt database (downloaded on April 22, 2009) using the Mascot software package
7 (version 2.2.1) (Matrix Science, London, UK). The search parameters used were as
8 follows: the human protein database was selected; up to one missed cleavage was
9 allowed; “none” was designated as the enzyme; mass tolerances for precursor and
10 fragment ions were \pm 0.6 Da and \pm 0.2 Da, respectively; the score threshold was set to P
11 $<$ 0.05 based on the size of the database used in the search. If a peptide matched
12 multiple proteins, the protein name with the highest Mascot score was selected.

13

14 **Immunoblot analysis**

15 Primary antibodies used were mouse monoclonal antibody against adipophilin
16 (LifeSpan Biosciences, Seattle, WA) and mouse monoclonal antibody against human
17 complement C3b- α (PROGEN, Heidelberg, Germany). Ten microliter of 1:50 diluted
18 plasma sample and 0.3 μ g of fully recombinant adipophilin (BioVendor, Modrice, Czech
19 Republic) as positive control were separated by SDS-PAGE and electroblotted onto a
20 polyvinylidene difluoride membrane. The membrane was then incubated with primary
21 antibody followed by horseradish peroxidase-conjugated anti-mouse IgG as described
22 previously (24, 25). Blots were developed using an enhanced chemiluminescence (ECL)
23 detection system (GE Healthcare, Buckinghamshire, UK).

24

25 **Reverse-phase protein microarray**

1 The plasma samples from the V1 and V2 cohorts were serially diluted 1:32, 1:64, 1:128,
2 and 1:256 using a Biomek 2000 Laboratory Automation Robot (Beckman Coulter,
3 Fullerton, CA), and randomly plotted onto ProteoChip[®] glass slides (Proteogen, Seoul,
4 Korea) in quadruplicate in a 6144-spot/slide format using a Protein Microarrayer Robot
5 (Kaken Geneqs, Matsudo, Japan). The spotted slides were incubated overnight with the
6 same primary antibody as used in Western blotting. The slides were incubated with
7 biotinylated anti-mouse IgG (Vector Laboratories, Burlingame, CA) followed by
8 streptavidin-horseradish peroxidase conjugate (GE Healthcare, Buckinghamshire, UK).
9 Peroxidase activity was detected using the Tyramide Signal Amplification (TSA[®])
10 Cyanine 5 System (PerkinElmer, Waltham, MA). The slides were counterstained with
11 Alexa Fluor[®] 546-labeled goat anti-human IgG (Invitrogen, Eugene, OR) (spotting
12 control).

13 The stained slides were scanned on a microarray scanner (InnoScan[®] 700AL,
14 Innopsys, Carbonne, France). Fluorescence intensity, determined as mean values of
15 quadruplicate samples, was determined using the Mapix[®] software (Innopsys, Carbonne,
16 France). All intensity values were transformed into logarithmic variables. The
17 reproducibility of our reverse-phase protein microarray assay was reported previously
18 (18).

19

20 **Immunohistochemistry**

21 Twenty colorectal cancer cases were selected from the surgical pathology archive panel
22 of the National Cancer Center Hospital, as described previously (24). Sections (4- μ m
23 thick) were cut from paraffin blocks of colorectal cancer tissues and mounted on
24 silanized glass slides, and were subsequently stained by the avidin-biotin complex
25 method. The primary antibody was the same as used in immunoblot analysis.

1

2 **Statistical analysis**

3 The statistical significance of inter-group differences was assessed with the Wilcoxon
4 test, Mann-Whitney *U*-test, Welch's *t*-test, Kruskal-Wallis test, or Fisher's exact test, as
5 appropriate. The area under the curve (AUC) value of the receiver operating
6 characteristics (ROC) analysis was calculated for each marker to evaluate its diagnostic
7 significance using ROCKIT software (version 0.9.1; the Kurt Rossmann Laboratories,
8 Chicago, IL). A composite index of two markers was generated using the result of
9 multivariate logistic regression analysis, which also enabled the calculation of
10 sensitivity, specificity, and ROC curves. Statistical analyses were performed using an
11 open-source statistical language R (version 2.7.0) with the optional module Design
12 package.

13

14

15 **Results**

16 **Plasma biomarker discovery by quantitative MS**

17 To identify a diagnostic biomarker for patients with colorectal cancer including those
18 with early-stage diseases, we compared the plasma proteomes of 22 colorectal cancer
19 patients with those of 21 healthy controls (Training cohort) using 2DICAL (Table 1).
20 Among a total of 53,009 independent MS peaks detected within the range 250-1,600
21 *m/z* and within the time range 20-70 minutes, we found 103 peaks with a discriminatory
22 AUC value of > 0.800. A representative 2-dimensional view of all the MS peaks, with
23 the *m/z* displayed along the X-axis and the LC retention time (RT) along the Y-axis, is
24 shown in Figure 1A. The 103 MS peaks which distinguished between colorectal cancer
25 patients and healthy controls with AUC values of > 0.800 are highlighted in red.

1 Eleven MS/MS spectra acquired from those 103 peaks matched six proteins in
2 the database with Mascot score > 40 (Supplementary Table S1). We focused attention on
3 a MS peak (ID 83) derived from the amino acid sequence of *ADFP* gene product
4 (Supplementary Fig. S1), because the expression level of adipophilin was previously
5 reported to be upregulated in clear cell renal carcinoma, but no such upregulation has
6 been described in colorectal cancer. The adipophilin-derived MS peak (ID 83, at 749
7 *m/z* and 47.4 minutes) in representative patients from cancer and control groups is
8 shown in Figure 1B. The distribution of the MS peak (ID 83) in patients with colorectal
9 cancer (*red*) and healthy controls (*blue*) in the Training cohort (AUC = 0.814) is shown
10 in Figure 1C. The differential expression and identification of adipophilin was
11 confirmed by denaturing SDS-PAGE and immunoblotting analyses (Fig. 1D).

12

13 **Protein microarray validation**

14 To further validate the utility of using adipophilin for the diagnosis of colorectal cancer,
15 the relative level of adipophilin in a total of 323 plasma samples was quantified using
16 reverse-phase protein microarrays (Fig. 2). Quadruplicate spots for representative cases
17 with high and low levels of adipophilin are shown in Figure 2. The power of plasma
18 adipophilin level to discriminate colorectal cancer was validated in two larger
19 independent Validation cohorts (V1: *n* = 210, V2: *n* = 113) that included early-stage
20 colorectal cancer (Table 1). In the V1 cohort, the adipophilin level was significantly
21 higher in patients with colorectal cancer than in healthy controls (Welch's *t*-test *P* =
22 5.49×10^{-10} , Fig. 3A and Table 1), with an AUC value of 0.767 [95% confidential
23 interval (CI): 0.699-0.825] (Fig. 3B). The colorectal cancer discriminatory power of
24 adipophilin was also apparent in the V2 cohort (*P* = 0.00009, Fig. 3C and Table 1), with
25 an AUC value of 0.742 [95% CI: 0.625-0.836] (Fig. 3B).

1 There was no difference in the plasma level of adipophilin among different
2 disease stages (Kruskal-Wallis test $P = 0.280$). Notably, however, the adipophilin level
3 was significantly higher even in patients with stage I or II disease (localized early
4 colorectal cancer without metastasis to lymph nodes) than in healthy controls, while the
5 CEA level in early-stage patients did not significantly differ from that of healthy
6 controls (Table 2).

7

8 **Adipophilin complements CEA**

9 The levels of adipophilin and CEA were not mutually correlated (Pearson's $r = 0.13$ in
10 the V1 cohort and 0.12 in the V2 cohort), and the AUC values of CEA in both cohorts
11 (Fig. 3D) were comparable to that of a previous report (26). Combining adipophilin and
12 CEA quantitation yielded a significant improvement in the ability to distinguish patients
13 with colorectal cancer from healthy controls compared to quantitating CEA alone; the
14 AUC improved to 0.849 [95% CI: 0.790-0.896] in the V1 cohort ($P = 0.0008$) and 0.787
15 [0.673-0.874] in the V2 cohort ($P = 0.022$) (Fig. 3D), indicating that plasma adipophilin
16 and CEA have complementary diagnostic utility.

17 Due to the low prevalence of colorectal cancer among an asymptomatic
18 population, a high specificity is required for a screening biomarker. If we defined the
19 upper limit of the normal range of the composite index (adipophilin plus CEA; Fig. 3D)
20 to include 95% of healthy controls in each validation cohort, the sensitivity of the index
21 was 54% [95% CI: 41-66%] in the V1 cohort and 31% [13-56%] in the V2 cohort.

22

23 **Adipophilin expression in colorectal cancer**

24 The expression and cellular distribution of adipophilin in colorectal cancer tissues were
25 examined using an immunohistochemical assay of eight well-differentiated, ten

1 moderately-differentiated, and two poorly-differentiated adenocarcinomas. A total of 14
2 of 20 cancer tissues from the well- and moderately-differentiated cases showed positive
3 staining for adipophilin, but neither of the two poorly-differentiated samples was
4 positive. In a majority of the well- and moderately-differentiated tumors, strong staining
5 for adipophilin was observed in the cytoplasm or cell membrane of tumor glands facing
6 the basement membrane (Fig. 4A and 4B). Adipophilin was not expressed in normal
7 epithelial cells of the colorectal mucosa (Fig. 4C). The expression of adipophilin was
8 clearly diminished in cancer cells invading in a scattered manner (Fig. 4D), which is
9 consistent with the lack of staining observed in poorly-differentiated tumor samples.

10

11

12 **DISCUSSION**

13 In the present study, we first enriched the LMW plasma protein fraction using HFMT,
14 then compared its contents between patients with colorectal cancer and healthy controls
15 using 2DICAL (Fig. 1). The high efficacy of combining HFMT and 2DICAL for plasma
16 biomarker discovery was demonstrated for the first time in our previous study of
17 pancreatic cancer (17), and the present results further strengthened the credible evidence
18 for the applicability of this combination of methods to all types of future plasma
19 biomarker research. Any biomarker candidate identified by proteomic approaches must
20 be validated using a different method in a statistically sufficient number of cases and
21 controls before it can be considered for clinical application. We employed another
22 innovative technology, a reverse-phase protein microarray, for independent validation of
23 our finding that adipophilin discriminates colorectal cancer (Fig. 2). Our high-density
24 protein microarray enabled the high-throughput quantification of one protein in
25 hundreds of clinical samples in one experiment (18), while keeping the required volume

1 of each sample to a minimum (nanoliter level). Although the availability of clinical
2 samples is often limited, it is often necessary to waste hundreds of microliters of
3 samples for preliminary experiments involving techniques such as conventional
4 enzyme-linked immunosorbent assay (ELISA). Because of their minimal sample
5 requirements, plasma microarrays are considered to be ideal alternatives to ELISAs for
6 biomarker validation. However, the absolute concentration and optimal cut-off value of
7 adipophilin were not determined in the present study. It may be necessary to establish an
8 ELISA prior to the clinical application of the present results.

9 Although the expression of adipophilin is known to be induced in various types
10 of pathological and physiological conditions such as lactating mammary epithelial cells,
11 few studies have assessed the significance of its expression in cancer cells (27, 28). We
12 found that adipophilin is expressed in well- or moderately-differentiated
13 adenocarcinomas, but not in the adjacent normal colonic mucosa or
14 poorly-differentiated adenocarcinoma (Fig. 4). The immunohistochemical data suggest
15 that the expression of adipophilin is induced during the process of early colorectal
16 carcinogenesis, but lost during the process of cancer promotion. Consistent with our
17 findings, Yao *et al.* also reported that adipophilin expression correlates well with the
18 differentiation status of clear cell renal carcinoma of the kidney (29). They also reported
19 that adipophilin expression is a prognostic factor for the cancer-specific survival of
20 patients with renal clear cell carcinoma (29). The prognostic significance of adipophilin
21 expression in colorectal cancer, however, remains to be determined.

22 The expression of adipophilin is known to be regulated by hypoxia inducible
23 factor (HIF) and the peroxisome proliferator-activated receptor (PPAR) family of
24 proteins. Both HIF and PPAR were reported to be closely involved in carcinogenesis,
25 especially in colorectal cancer (30, 31). Moreover, PPAR γ may be a molecular target of

1 anticancer therapy (32). Since the exact nature of the interactions between these proteins
2 (adipophilin, HIF, and PPAR) has not been extensively investigated, further studies are
3 needed to elucidate the biological and clinicopathological significance of adipophilin
4 expression in colorectal cancer. The present findings may provide novel insights into the
5 molecular mechanism of colorectal cancer development and progression and into the
6 development of new anticancer therapeutics.

7 There are some limitations to our study. First, we have no data regarding the
8 body-mass index of cases included in the present study. The relationship between
9 obesity and an increased risk of colon cancer is now generally accepted (33-35), and
10 alteration of adipocytokine levels can reportedly affect intestinal carcinogenesis (36).
11 Although adipophilin was originally identified as a marker of adipocyte development
12 (27, 37), its relevance to body shape and cachexia remain to be elucidated. Adipophilin
13 is a 50 kDa protein belonging to the PAT family (perilipin, adipophilin, TIP47, S3-12,
14 and OXPAT), which comprises proteins involved in the coating of lipid droplets (27, 38,
15 39). Secondly, we have no data of FOB test results for the cases used in this study, and
16 thus it was not possible to demonstrate the superiority of adipophilin to FOB. However,
17 a recent large-scale study demonstrated that 11% of patients with negative FOB results
18 had cancers or adenomas that required treatment (40). Since the adipophilin level was
19 significantly elevated even in patients with localized early colorectal cancer (Table 2),
20 adipophilin may supplement or surpass the diagnostic power of FOB. Finally, there was
21 a difference in the age distribution between cancer and control in all cohorts. However,
22 age did not correlate with plasma adipophilin level in the cancer and control group
23 (Pearson's $r = 0.03$ and $r = 0.09$, respectively). We therefore estimate the influence of
24 difference in age to be negligible.

25 In conclusion, we identified plasma adipophilin as a new tumor marker for

1 colorectal cancer using LMW protein profiling. The increase of plasma adipophilin
2 level in colorectal cancer was validated in two larger cohorts, and the diagnostic power
3 was revealed to be superior to that of CEA in the detection of early-stage (stages I and
4 II) colorectal cancer. To our knowledge, this is the first study demonstrating the
5 expression of adipophilin in colorectal cancer. While bearing the above limitations in
6 mind, an independent validation study is warranted.

7

8

9

10 **Acknowledgements**

11 We thank Ms. Ayako Igarashi, Ms. Tomoko Umaki, and Ms. Yuka Nakamura for their
12 technical assistance.

13

14 **Grant support**

15 This study was supported by the “Program for Promotion of Fundamental Studies in
16 Health Sciences” conducted by the National Institute of Biomedical Innovation of Japan,
17 the “Third-Term Comprehensive Control Research for Cancer” and “Research on
18 Biological Markers for New Drug Development” conducted by the Ministry of Health
19 and Labor of Japan. These sponsors had no role in the design of the study, data
20 collection, data analysis and interpretation, the decision to submit the manuscript for
21 publication, or the writing of the manuscript.

22

23 **References**

24 1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, *et al.* Cancer statistics, 2008. *CA*
25 *Cancer J Clin* 2008;58: 71-96.

- 1 2. Ministry of Health, Labour and Welfare. Japanese Government: Vital Statistics of
2 Japan 2009;
3 [http://ganjoho.ncc.go.jp/professional/statistics/odjrh3000000hwsa-att/cancer_mortality\(1958-20](http://ganjoho.ncc.go.jp/professional/statistics/odjrh3000000hwsa-att/cancer_mortality(1958-20)
4 [08\).xls](http://ganjoho.ncc.go.jp/professional/statistics/odjrh3000000hwsa-att/cancer_mortality(1958-2008).xls).
- 5 3. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, *et al.* Improved
6 overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or
7 III colon cancer in the MOSAIC trial. *J Clin Oncol* 2009;27: 3109-16.
- 8 4. Wolmark N, Yothers G, O'Connell MJ, Sharif S, Atkins JN, Seay TE, *et al.* A phase III
9 trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of
10 the colon: Results of NSABP Protocol C-08. *J Clin Oncol* 2009;27 (18s): suppl; abstr LBA4.
- 11 5. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, *et al.*
12 Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. *N Engl J Med*
13 2009;360: 563-72.
- 14 6. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, *et al.*
15 Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon
16 Cancer Control Study. *N Engl J Med* 1993;328: 1365-71.
- 17 7. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of
18 screening for colorectal cancer with faecal-occult-blood test. *Lancet* 1996;348: 1467-71.
- 19 8. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, *et*
20 *al.* Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. *Lancet*
21 1996;348: 1472-7.
- 22 9. Greenberg PD, Bertario L, Gnauck R, Kronborg O, Hardcastle JD, Epstein MS, *et al.*
23 A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing
24 colonoscopy. *Am J Gastroenterol* 2000;95: 1331-8.
- 25 10. van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH,

- 1 *et al.* Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal
2 cancer in a screening population. *Gastroenterology* 2008;135: 82-90.
- 3 11. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, *et al.* ASCO
4 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. *J Clin*
5 *Oncol* 2006;24: 5313-27.
- 6 12. Yamaguchi U, Nakayama R, Honda K, Ichikawa H, Hasegawa T, Shitashige M, *et al.*
7 Distinct gene expression-defined classes of gastrointestinal stromal tumor. *J Clin Oncol*
8 2008;26: 4100-8.
- 9 13. Ono M, Shitashige M, Honda K, Isobe T, Kuwabara H, Matsuzuki H, *et al.* Label-free
10 quantitative proteomics using large peptide data sets generated by nanoflow liquid
11 chromatography and mass spectrometry. *Mol Cell Proteomics* 2006;5: 1338-47.
- 12 14. Matsubara J, Ono M, Negishi A, Ueno H, Okusaka T, Furuse J, *et al.* Identification of
13 a predictive biomarker for hematologic toxicities of gemcitabine. *J Clin Oncol* 2009;27: 2261-8.
- 14 15. Negishi A, Ono M, Handa Y, Kato H, Yamashita K, Honda K, *et al.* Large-scale
15 quantitative clinical proteomics by label-free liquid chromatography and mass spectrometry.
16 *Cancer Sci* 2009;100: 514-9.
- 17 16. Ono M, Matsubara J, Honda K, Sakuma T, Hashiguchi T, Nose H, *et al.* Prolyl
18 4-hydroxylation of alpha-fibrinogen: a novel protein modification revealed by plasma
19 proteomics. *J Biol Chem* 2009;284: 29041-9.
- 20 17. Matsubara J, Honda K, Ono M, Tanaka Y, Kobayashi M, Jung G, *et al.* Reduced
21 plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer. *Cancer Epidemiol*
22 *Biomarkers Prev* 2011;20: 160-71.
- 23 18. Matsubara J, Ono M, Honda K, Negishi A, Ueno H, Okusaka T, *et al.* Survival
24 prediction for pancreatic cancer patients receiving gemcitabine treatment. *Mol Cell Proteomics*
25 2010;9: 695-704.

- 1 19. Kennedy S. The role of proteomics in toxicology: identification of biomarkers of
2 toxicity by protein expression analysis. *Biomarkers* 2002;7: 269-90.
- 3 20. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD.
4 Characterization of the low molecular weight human serum proteome. *Mol Cell Proteomics*
5 2003;2: 1096-103.
- 6 21. Anderson NL, Anderson NG. The human plasma proteome: history, character, and
7 diagnostic prospects. *Mol Cell Proteomics* 2002;1: 845-67.
- 8 22. Tanaka Y, Akiyama H, Kuroda T, Jung G, Tanahashi K, Sugaya H, *et al.* A novel
9 approach and protocol for discovering extremely low-abundance proteins in serum. *Proteomics*
10 2006;6: 4845-55.
- 11 23. http://www.fhcr.org/science/international_biomarker/.
- 12 24. Honda K, Yamada T, Hayashida Y, Idogawa M, Sato S, Hasegawa F, *et al.* Actinin-4
13 increases cell motility and promotes lymph node metastasis of colorectal cancer.
14 *Gastroenterology* 2005;128: 51-62.
- 15 25. Idogawa M, Yamada T, Honda K, Sato S, Imai K, Hirohashi S. Poly(ADP-ribose)
16 polymerase-1 is a component of the oncogenic T-cell factor-4/beta-catenin complex.
17 *Gastroenterology* 2005;128: 1919-36.
- 18 26. Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Jarvinen H, Haglund C.
19 Estimating the probability of cancer with several tumor markers in patients with colorectal
20 disease. *Oncology* 2004;66: 296-302.
- 21 27. Heid HW, Moll R, Schwetlick I, Rackwitz HR, Keenan TW. Adipophilin is a specific
22 marker of lipid accumulation in diverse cell types and diseases. *Cell Tissue Res* 1998;294:
23 309-21.
- 24 28. de Wilde J, Smit E, Snepvangers FJ, de Wit NW, Mohren R, Hulshof MF, *et al.*
25 Adipophilin protein expression in muscle - a possible protective role against insulin resistance.

- 1 FEBS J 2010 in press.
- 2 29. Yao M, Huang Y, Shioi K, Hattori K, Murakami T, Nakaigawa N, *et al.* Expression of
3 adipose differentiation-related protein: a predictor of cancer-specific survival in clear cell renal
4 carcinoma. *Clin Cancer Res* 2007;13: 152-60.
- 5 30. Paul SA, Simons JW, Mabweesh NJ. HIF at the crossroads between ischemia and
6 carcinogenesis. *J Cell Physiol* 2004;200: 20-30.
- 7 31. Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, Kawamori T, *et al.*
8 Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis
9 induced by azoxymethane in mice. *Gastroenterology* 2003;124: 361-7.
- 10 32. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome
11 proliferator-activated receptor gamma agonists. *Lancet Oncol* 2004;5: 419-29.
- 12 33. Pischon T, Lahmann PH, Boeing H, Friedenreich C, Norat T, Tjonneland A, *et al.*
13 Body size and risk of colon and rectal cancer in the European Prospective Investigation Into
14 Cancer and Nutrition (EPIC). *J Natl Cancer Inst* 2006;98: 920-31.
- 15 34. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in
16 cancers of the colon, prostate, and pancreas. *Gastroenterology* 2007;132: 2208-25.
- 17 35. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and
18 incidence of cancer: a systematic review and meta-analysis of prospective observational studies.
19 *Lancet* 2008;371: 569-78.
- 20 36. Mutoh M, Teraoka N, Takasu S, Takahashi M, Onuma K, Yamamoto M, *et al.* Loss of
21 Adiponectin Promotes Intestinal Carcinogenesis in Minand Wild-type Mice. *Gastroenterology*
22 2011 *in press*.
- 23 37. Brasaemle DL. Thematic review series: adipocyte biology. The perilipin family of
24 structural lipid droplet proteins: stabilization of lipid droplets and control of lipolysis. *J Lipid*
25 *Res* 2007;48: 2547-59.

- 1 38. Jiang HP, Serrero G. Isolation and characterization of a full-length cDNA coding for an
2 adipose differentiation-related protein. *Proc Natl Acad Sci U S A* 1992;89: 7856-60.
- 3 39. Martin S, Parton RG. Lipid droplets: a unified view of a dynamic organelle. *Nat Rev*
4 *Mol Cell Biol* 2006;7: 373-8.
- 5 40. Johnson CD, Chen MH, Toledano AY, Heiken JP, Dachman A, Kuo MD, *et al.*
6 Accuracy of CT colonography for detection of large adenomas and cancers. *N Engl J Med*
7 2008;359: 1207-17.
- 8
- 9
- 10

1 **FIGURE LEGENDS**

2 **Figure 1.**

3 **(A)** Two-dimensional display of all (>53,000) MS peaks detected. The 103 MS peaks
4 for which the mean intensity determined in duplicate analyses distinguished between
5 colorectal cancer and healthy control patients (with AUC values >0.800) are highlighted
6 in red.

7 **(B)** Adipophilin-derived MS peaks in representative patients from cancer and control
8 groups. Arrows indicate ID 83, at 749 *m/z* and a RT of 47.4 minutes.

9 **(C)** Adipophilin-derived MS peaks (ID 83) in 43 duplicate LC-MS runs aligned
10 according to RT (*top*). Columns represent the mean intensity of duplicate analyses of the
11 43 individuals in the Training cohort (*bottom*).

12 **(D)** Verification of quantitative MS data and protein identification. The levels of plasma
13 adipophilin and complement C3b- α (loading control) were determined using
14 immunoblotting in representative colorectal cancer patients and healthy individuals
15 selected from the Training cohort. Recombinant adipophilin (0.3 μ g) was applied as a
16 positive control (lane next to the molecular weight standard ladder).

17

18 **Figure 2.**

19 Representative reverse-phase protein microarray slide of the V1 cohort stained with
20 anti-ADFP antibody (*left*). Magnified images of quadruplicate spots of representative
21 individuals with high and low levels of adipophilin (*right*).

22

23 **Figure 3.**

24 **(A, C)** Plasma adipophilin level in healthy controls and patients with colorectal cancer
25 in the V1 (A) and V2 (C) cohorts. Horizontal lines represent the average adipophilin

1 level.

2 **(B)** ROC analyses illustrating the discriminatory capability of adipophilin in the V1
3 (*solid line*) and V2 (*dashed line*) cohorts.

4 **(D)** ROC analyses illustrating the discriminatory value of CEA and the composite index
5 of adipophilin and CEA in the V1 and V2 cohorts.

6

7 **Figure 4.**

8 Immunohistochemical analysis of adipophilin in colorectal cancer (A-D) and adjacent
9 normal colonic mucosa (designated by N) (C).

10 Original magnification; A and D = 100×; B = 400×; C = 40×.

11

12

1 **LIST OF TABLES**

2 **Table 1.** Clinicopathologic Characteristics of Cases in the Training ($n = 43$) and
3 Validation Cohorts (V1: $n = 210$; V2: $n = 113$).

4

5 **Table 2.** Plasma Adipophilin and CEA Levels According to Clinical Stage of
6 Colorectal Cancer [International Union Against Cancer (UICC) TNM Classification of
7 Malignant Tumours, 6th edition (2002)] in the V1 Cohort.


8

9

Figure 1

A



■ Peaks with AUC > 0.800




B

Healthy Control

Colorectal Cancer



C



D




Figure 2





Figure 3

A



B





Figure 3

C



D




Figure 4




Table 1. Clinicopathologic Characteristics of Cases in the Training and Validation Cohorts

| | Training Cohort (<i>n</i> = 43) | | | Validation-1 Cohort (<i>n</i> = 210) | | | Validation-2 Cohort (<i>n</i> = 113) | | |
|---|----------------------------------|---------|---------------------|---------------------------------------|-------------|----------------------|---------------------------------------|-------------|----------------------|
| | Cancer | Healthy | <i>P</i> | Cancer | Healthy | <i>P</i> | Cancer | Healthy | <i>P</i> |
| No. of patients | 22 | 21 | | 101 | 109 | | 26 | 87 | |
| Sex, no. of patients | | | 0.310* | | | 0.782* | | | 0.252* |
| Male | 14 | 17 | | 63 | 70 | | 13 | 56 | |
| Female | 8 | 4 | | 38 | 39 | | 13 | 31 | |
| Age, years | | | <0.001 | | | <0.001 | | | <0.001 |
| mean (SD) | 62 (12) | 40 (13) | | 64 (11) | 42 (14) | | 63 (12) | 43 (16) | |
| Tumor location | | | NA | | | NA | | | NA |
| Colon | 22 | — | | 88 | — | | 24 | — | |
| Rectum | 0 | — | | 13 | — | | 2 | — | |
| Clinical stage | | | NA | | | NA | | | NA |
| I | 3 | — | | 19 | — | | 12 | — | |
| II | 6 | — | | 31 | — | | 5 | — | |
| III | 8 | — | | 32 | — | | 8 | — | |
| IV | 5 | — | | 17 | — | | 1 | — | |
| unknown | 0 | — | | 2 | — | | 0 | — | |
| CA19-9 | | | | | | | | | |
| median, U/mL | 14.7 | 5.5 | 0.010 | 4 | 1.6 | <0.001 | 9.4 | 10.2 | 0.680 |
| >37.0 (ULN), no. of patients | 6 | 2 | | 39 | 5 | | 2 | 4 | |
| CEA | | | | | | | | | |
| median, ng/mL | 3.5 | 1.7 | 0.002 | 11.8 | 7.6 | 0.001 | 2.6 | 1.7 | 0.008 |
| >5.0 (ULN), no. of patients | 9 | 1 | | 24 | 5 | | 4 | 5 | |
| Total bilirubin | | | | | | | | | |
| median, mg/dL | 0.4 | 0.5 | 0.114 | 0.4 | 0.5 | <0.001 | 0.4 | 0.5 | <0.001 |
| >1.2 (ULN), no. of patients | 0 | 0 | | 1 | 3 | | 0 | 4 | |
| Adipophilin | | | | | | | | | |
| Mass spectrometry peak intensity [†] , mean (SD) | 320 (375) | 96 (78) | <0.001 [§] | — | — | | — | — | |
| Protein intensity [‡] , mean (SD) | — | — | | 3.91 (0.06) | 3.82 (0.13) | <0.001 | 3.57 (0.14) | 3.42 (0.20) | <0.001 |

NOTE. Wilcoxon test was applied to assess differences between values. *Calculated by Fisher's exact test. †Intensity of the corresponding peak as measured using quantitative mass spectrometry.

‡Measured using reverse-phase protein microarray (logarithmic variable). §Calculated using Mann-Whitney *U*-test. ||Calculated using Welch's *t*-test.

Abbreviations: SD, standard deviation; NA, not applicable; ULN, upper limit of normal.

Table 2. Plasma Adipophilin and CEA Levels According to Clinical Stage of Colorectal Cancer (V1 Cohort)

| | Colorectal Cancer Patients | | | | Healthy Controls |
|---|----------------------------|-----------------------|-----------------------|------------------------|------------------|
| | Stage I | Stage II | Stage III | Stage IV | |
| No. of cases | 19 | 31 | 32 | 17 | 109 |
| Adipophilin[*], mean (SD) | 3.90 (0.05) | 3.91 (0.07) | 3.91 (0.07) | 3.93 (0.03) | 3.82 (0.13) |
| <i>P</i> † (vs. healthy controls) | 1.07×10 ⁻⁵ | 3.31×10 ⁻⁶ | 1.65×10 ⁻⁶ | 2.27×10 ⁻¹¹ | — |
| CEA, mean (SD), ng/mL | 2.63 (1.71) | 13.7 (36.2) | 224 (1068) | 200 (579) | 2.07 (1.74) |
| <i>P</i> † (vs. healthy controls) | 0.20 | 0.09 | 0.25 | 0.18 | — |

*Measured using a reverse-phase protein microarray (values were transformed into logarithmic variables).

†Welch's t-test (comparison to healthy controls).

Abbreviation: SD, standard deviation.

LEGEND FOR SUPPLEMENTARY FIGURE

Supplementary Figure S1 (online).

MS/MS spectra and database search result for a single MS peak (ID 83) derived from adipophilin. The adipophilin peptide matching the amino acid sequence in the database is highlighted in red (*bottom*).

LIST OF TABLES

Supplementary Table S1 (online).

Plasma Proteins for which the MS Peak Intensity Differed Significantly between Healthy Controls and Patients with Colorectal Cancer.


Supplementary Figure S1

Peak ID: 83

MS/MS Fragmentation of **EMAENGV**

Found in **ADFP_HUMAN**, Adipophilin (Adipose differentiation-related protein) (ADRP) - Homo sapiens (Human)

Match to Query 2: 748.347984 from(749.355260,1+)



Monoisotopic mass of neutral peptide Mr(calc): 748.3061

Ions Score: 44 Expect: 0.21

Matches (Bold Red): 10/26 fragment ions using 25 most intense peaks

| # | a | a* | b | b* | Seq. | y | y* | # |
|---|-----------------|----------|-----------------|----------|----------|-----------------|----------|---|
| 1 | 102.0550 | | 130.0499 | | E | | | 7 |
| 2 | 233.0954 | | 261.0904 | | M | 620.2708 | 603.2443 | 6 |
| 3 | 304.1326 | | 332.1275 | | A | 489.2304 | 472.2038 | 5 |
| 4 | 433.1751 | | 461.1701 | | E | 418.1932 | 401.1667 | 4 |
| 5 | 547.2181 | 530.1915 | 575.2130 | 558.1864 | N | 289.1506 | 272.1241 | 3 |
| 6 | 604.2395 | 587.2130 | 632.2345 | 615.2079 | G | 175.1077 | | 2 |
| 7 | | | | | V | 118.0863 | | 1 |

Matched peptides shown in **Bold Red**

```
1 MASVAVDPQP SVVTRVNVNLP LVSSTYDLMS SAYLSTKDQY PYLKSVCEMA
51 ENGVKTITTSV AMTSALPIIQ KLEPQIAVAN TYACKGLDRI EERLPILNQF
101 STQIVANAKG AVTGAKDAVT TTVTGAKDSV ASTITGVMDK TKGAVTGSVE
151 KTKSVVSGSI NTVLGSRRMQ LVSSGVENAL TKSELLVEQY LPLTEEELEK
201 EAKKVEGFDL VQKPSYYVRL GSLSTKLHSR AYQQALSRVK EAKQKSQQTI
251 SQLHSTVHLI EFARKNVYSA NQKIQDAQDK LYLSWVEWKR SIGYDDTDES
301 HCAEHIESRT LAIARNLTQQ LQTTCHTLLS NIQGVQNIQ DQAKHMGVMA
351 GDIYSVFRNA ASFKEVSDSL LTSSKGQLQK MKESLDDVMD YLVNNTPLNW
401 LVGPFYPQLT ESQNAQDQGA EMDKSSQETQ RSEHKTH
```

Supplementary Table S1. Plasma Proteins for which the MS Peak Intensity Differed Significantly Between Healthy Controls and Patients with Colorectal Cancer

| Gene locus | Protein identification | Mascot score | AUC | Matched peptide |
|-------------------|---|---------------------|------------|------------------------|
| HBD HUMAN | Hemoglobin subunit delta (Hemoglobin delta chain) (Delta-globin) - Homo sapiens (Human) | 90.18 | 0.86 | 1 |
| HBB HUMAN | Hemoglobin subunit beta (Hemoglobin beta chain) (Beta-globin) - Homo sapiens (Human) | 74.50 | 0.82 | 5 |
| RETBP_HUMAN | Plasma retinol-binding protein precursor (PRBP) (RBP) [Contains: Plasma retinol-binding protein (1-182); Plasma retinol-binding protein (1-181); Plasma retinol-binding protein (1-179); Plasma retinol-binding protein (1-176)] - Homo sapiens (Human) | 66.52 | 0.82 | 1 |
| HBA HUMAN | Hemoglobin subunit alpha (Hemoglobin alpha chain) (Alpha-globin) - Homo sapiens (Human) | 63.75 | 0.81 | 2 |
| ADFP HUMAN | Adipophilin (Adipose differentiation-related protein) (ADRP) - Homo sapiens (Human) | 43.67 | 0.81 | 1 |
| PKDRE_HUMAN | Polycystic kidney disease and receptor for egg jelly-related protein precursor (PKD and REJ homolog) - Homo sapiens (Human) | 41.62 | 0.81 | 1 |

NOTE. *Peaks with a Mascot score >40.